FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072903085> ?p ?o ?g. }

• W2072903085 endingPage "458" @default.
• W2072903085 startingPage "452" @default.
• W2072903085 abstract "Background— A potentially strong association exists between Chlamydia pneumoniae and atherosclerosis, but the clinical benefits of antibiotic therapy have not been demonstrated. Preliminary studies of antibiotic therapy in peripheral artery disease have shown a decreased need for revascularization and improved walking ability. The objective of this phase-III trial was to assess the effect of a potent anti-Chlamydial agent, rifalazil, on peak walking time in patients with symptomatic peripheral artery disease. Methods and Results— Patients with intermittent claudication secondary to peripheral artery disease who were seropositive for C pneumoniae were randomized to 25 mg rifalazil once weekly for 8 weeks or matching placebo. Two hundred ninety-seven patients were enrolled from 3 countries and were followed up for 1 year. The mean±SD ankle brachial index at baseline was 0.63±0.16. The primary end point, change from baseline in log peak walking time on a graded treadmill, was assessed 180 days after randomization. Secondary end points included changes in claudication onset time and quality of life, assessed with the Walking Impairment Questionnaire and the Short Form Medical Outcomes 36. No benefit of rifalazil therapy was found in the primary or any secondary end point among this cohort of patients with peripheral artery disease. The group treated with rifalazil improved their peak walking times by 23% (95% confidence interval, 15 to 31) from baseline to day 180, whereas the placebo group improved by 18% (95% confidence interval, 11 to 26; P =0.38). Peak walking time, claudication onset time, Walking Impairment Questionnaire, and Short Form Medical Outcomes 36 showed no treatment-by-time interaction during the 360-day study period. Thirty-two adjudicated cardiovascular events occurred, 16 in each treatment group. Conclusions— Rifalazil did not improve exercise performance or quality of life in patients with intermittent claudication. No safety concerns were identified. Given the very small effect size, it is unlikely that larger studies would demonstrate a symptomatic benefit of this therapy in peripheral artery disease." @default.
• W2072903085 created "2016-06-24" @default.
• W2072903085 creator A5016990383 @default.
• W2072903085 creator A5040084729 @default.
• W2072903085 creator A5040308280 @default.
• W2072903085 creator A5056183044 @default.
• W2072903085 creator A5065985671 @default.
• W2072903085 creator A5076746946 @default.
• W2072903085 creator A5090061685 @default.
• W2072903085 date "2009-01-27" @default.
• W2072903085 modified "2023-09-25" @default.
• W2072903085 title "Anti-Chlamydial Antibiotic Therapy for Symptom Improvement in Peripheral Artery Disease" @default.
• W2072903085 cites W1964926300 @default.
• W2072903085 cites W1973498254 @default.
• W2072903085 cites W1974487821 @default.
• W2072903085 cites W1983908302 @default.
• W2072903085 cites W1994676587 @default.
• W2072903085 cites W1994710013 @default.
• W2072903085 cites W2016712253 @default.
• W2072903085 cites W2023441499 @default.
• W2072903085 cites W2025447518 @default.
• W2072903085 cites W2050474359 @default.
• W2072903085 cites W2057244473 @default.
• W2072903085 cites W2089160521 @default.
• W2072903085 cites W2089859213 @default.
• W2072903085 cites W2117490971 @default.
• W2072903085 cites W2138998943 @default.
• W2072903085 cites W2140136269 @default.
• W2072903085 cites W2145315285 @default.
• W2072903085 cites W2147170567 @default.
• W2072903085 cites W2153132443 @default.
• W2072903085 cites W2157205193 @default.
• W2072903085 cites W2164556572 @default.
• W2072903085 cites W2164661188 @default.
• W2072903085 cites W2171009402 @default.
• W2072903085 cites W2386099697 @default.
• W2072903085 cites W2887712073 @default.
• W2072903085 cites W4235355439 @default.
• W2072903085 doi "https://doi.org/10.1161/circulationaha.108.815308" @default.
• W2072903085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19139383" @default.
• W2072903085 hasPublicationYear "2009" @default.
• W2072903085 type Work @default.
• W2072903085 sameAs 2072903085 @default.
• W2072903085 citedByCount "37" @default.
• W2072903085 countsByYear W20729030852012 @default.
• W2072903085 countsByYear W20729030852013 @default.
• W2072903085 countsByYear W20729030852014 @default.
• W2072903085 countsByYear W20729030852015 @default.
• W2072903085 countsByYear W20729030852016 @default.
• W2072903085 countsByYear W20729030852018 @default.
• W2072903085 countsByYear W20729030852019 @default.
• W2072903085 countsByYear W20729030852020 @default.
• W2072903085 crossrefType "journal-article" @default.
• W2072903085 hasAuthorship W2072903085A5016990383 @default.
• W2072903085 hasAuthorship W2072903085A5040084729 @default.
• W2072903085 hasAuthorship W2072903085A5040308280 @default.
• W2072903085 hasAuthorship W2072903085A5056183044 @default.
• W2072903085 hasAuthorship W2072903085A5065985671 @default.
• W2072903085 hasAuthorship W2072903085A5076746946 @default.
• W2072903085 hasAuthorship W2072903085A5090061685 @default.
• W2072903085 hasBestOaLocation W20729030851 @default.
• W2072903085 hasConcept C126322002 @default.
• W2072903085 hasConcept C141071460 @default.
• W2072903085 hasConcept C142724271 @default.
• W2072903085 hasConcept C164705383 @default.
• W2072903085 hasConcept C168563851 @default.
• W2072903085 hasConcept C1862650 @default.
• W2072903085 hasConcept C203092338 @default.
• W2072903085 hasConcept C204787440 @default.
• W2072903085 hasConcept C27081682 @default.
• W2072903085 hasConcept C2777466421 @default.
• W2072903085 hasConcept C2778963770 @default.
• W2072903085 hasConcept C2779881954 @default.
• W2072903085 hasConcept C3018348675 @default.
• W2072903085 hasConcept C44249647 @default.
• W2072903085 hasConcept C71924100 @default.
• W2072903085 hasConceptScore W2072903085C126322002 @default.
• W2072903085 hasConceptScore W2072903085C141071460 @default.
• W2072903085 hasConceptScore W2072903085C142724271 @default.
• W2072903085 hasConceptScore W2072903085C164705383 @default.
• W2072903085 hasConceptScore W2072903085C168563851 @default.
• W2072903085 hasConceptScore W2072903085C1862650 @default.
• W2072903085 hasConceptScore W2072903085C203092338 @default.
• W2072903085 hasConceptScore W2072903085C204787440 @default.
• W2072903085 hasConceptScore W2072903085C27081682 @default.
• W2072903085 hasConceptScore W2072903085C2777466421 @default.
• W2072903085 hasConceptScore W2072903085C2778963770 @default.
• W2072903085 hasConceptScore W2072903085C2779881954 @default.
• W2072903085 hasConceptScore W2072903085C3018348675 @default.
• W2072903085 hasConceptScore W2072903085C44249647 @default.
• W2072903085 hasConceptScore W2072903085C71924100 @default.
• W2072903085 hasIssue "3" @default.
• W2072903085 hasLocation W20729030851 @default.
• W2072903085 hasLocation W20729030852 @default.
• W2072903085 hasOpenAccess W2072903085 @default.
• W2072903085 hasPrimaryLocation W20729030851 @default.
• W2072903085 hasRelatedWork W1965911612 @default.
• W2072903085 hasRelatedWork W1967550664 @default.

• next